Pharmaceuticals & Therapeutics

Picard Medical rings the NYSE bell, but its stock's volatile journey reflects the high-stakes gamble on its next-generation artificial heart technology.

The biotech upstart will present a bold pipeline, including a head-to-head trial against a market leader and a first-in-class autoimmune eye disease therapy.

Dr. Philip Golinsky’s alumni award from Life University marks a milestone for RxWellness and the growing trend of integrated, non-surgical patient care.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

Celltrion's SteQeyma autoinjector gets a CHMP nod, enhancing patient care and intensifying competition in Europe's crowded biosimilar market.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

Following a failed takeover bid, vaccine maker Bavarian Nordic appoints Heidi Hunter as Vice Chair, signaling a strategic pivot in its top leadership.

With a former U.S. CTO, WHO expert, and life sciences vet, Welldoc is assembling a powerhouse team to dominate the AI-driven cardiometabolic care market.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

New rankings name Germany's top cancer hospitals, but the real story is the rise of platforms shaping a multi-billion dollar global health market.

CMS's new ACCESS model spotlights virtual care, positioning firms like FlyteHealth to lead a tech-driven transformation in managing chronic illness.

After a NYSE delisting, FOXO Technologies is betting big on healthcare acquisitions. Is this a savvy turnaround or a high-risk gamble for investors?

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.